Study of a drug to prevent low white blood cells after chemotherapy
Part of Blood & lymphatic, Cancer, Lungs & breathing clinical trials.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIB or IV non-small cell lung cancer (NSCLC) that has not been treated with chemotherapy or radiation before.
- You are scheduled to receive a specific type of chemotherapy that includes a platinum drug and a taxane drug, possibly with immunotherapy or anti-angiogenic therapy.
- You have additional risk factors for febrile neutropenia, such as being 65 or older, having poor nutrition, or a reduced ability to perform daily activities (ECOG score of 2 or higher).
- Your blood counts and organ function are within acceptable ranges, and you have not used certain blood cell-boosting medications recently.
- You do not have active infections, other types of cancer, or certain heart conditions.
- You are not pregnant and agree to use reliable birth control during the study and for 8 weeks after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a drug called G-CSF affects certain immune cells (MDSCs) and cancer stem cells in people with a specific type of advanced lung cancer (adenocarcinoma). It may help doctors understand how to make current treatments work better.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This trial tests a medication (Efbemalenograstim alfa) that helps boost your white blood cell counts during chemotherapy for ovarian or cervical cancer. It aims to reduce the risk of serious infections (febrile neutropenia) while you receive standard treatment with paclitaxel plus carboplatin or cisplatin, with or without bevacizumab.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.